Drugs interactions for Emgality®
- 0 Major drug interactions
- 1 Moderate drug interactions (including ingredients like Pozelimab)
- 156 Minor drug interactions (including ingredients like Adalimumab, Aducanumab, Alemtuzumab)
157 interactions for Emgality®The serum concentration of Pozelimab can be decreased when it is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Adalimumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Aducanumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Alirocumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Amivantamab.The risk or severity of adverse effects can be increased when Anifrolumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Ansuvimab.The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Atezolizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Atoltivimab.The risk or severity of adverse effects can be increased when Avelumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Axatilimab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Bamlanivimab.The risk or severity of adverse effects can be increased when Basiliximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Belimumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Benralizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Bimekizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Blinatumomab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Brodalumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Brolucizumab.The risk or severity of adverse effects can be increased when Burosumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Canakinumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Caplacizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Cemiplimab.The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Cetuximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Cilgavimab.Conjugated estrogens may increase the thrombogenic activities of Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Crovalimab.The risk or severity of adverse effects can be increased when Daratumumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Denosumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Dinutuximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Donanemab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Dostarlimab.The risk or severity of adverse effects can be increased when Dulaglutide is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Dupilumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Durvalumab is combined with Galcanezumab.The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Galcanezumab.The risk or severity of adverse effects can be increased when Eculizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Eflapegrastim.The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Elotuzumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Emapalumab.The risk or severity of adverse effects can be increased when Emicizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Eptinezumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Erenumab is combined with Galcanezumab.Esterified estrogens may increase the thrombogenic activities of Galcanezumab.Estetrol may increase the thrombogenic activities of Galcanezumab.Estradiol may increase the thrombogenic activities of Galcanezumab.Estradiol acetate may increase the thrombogenic activities of Galcanezumab.Estradiol cypionate may increase the thrombogenic activities of Galcanezumab.Estradiol valerate may increase the thrombogenic activities of Galcanezumab.Estriol may increase the thrombogenic activities of Galcanezumab.Estrone sulfate may increase the thrombogenic activities of Galcanezumab.Ethinylestradiol may increase the thrombogenic activities of Galcanezumab.The risk or severity of adverse effects can be increased when Evolocumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Fanolesomab.The risk or severity of adverse effects can be increased when Fremanezumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Glofitamab.The risk or severity of adverse effects can be increased when Golimumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Guselkumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ibalizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Idarucizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Inebilizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Infliximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ipilimumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Isatuximab.The risk or severity of adverse effects can be increased when Ixekizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Lanadelumab.The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Lecanemab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Loncastuximab tesirine.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Maftivimab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Margetuximab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Marstacimab.The risk or severity of adverse effects can be increased when Mepolizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Mosunetuzumab.The risk or severity of adverse effects can be increased when Natalizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Necitumumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Nemolizumab.The serum concentration of Galcanezumab can be decreased when it is combined with Nipocalimab.The risk or severity of adverse effects can be increased when Nivolumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Odesivimab.The risk or severity of adverse effects can be increased when Ofatumumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Olaratumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Omalizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Palivizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Panitumumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Penpulimab.The risk or severity of adverse effects can be increased when Pertuzumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ramucirumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ranibizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ravulizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Raxibacumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Relatlimab.The risk or severity of adverse effects can be increased when Reslizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Risankizumab.The risk or severity of adverse effects can be increased when Rituximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Romosozumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Rozanolixizumab.The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Sarilumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Secukinumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Siltuximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Sotatercept is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Sotrovimab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Spesolimab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Sutimlimab.Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Galcanezumab.Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tafasitamab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Telisotuzumab vedotin.The risk or severity of adverse effects can be increased when Teplizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Teprotumumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tezepelumab.The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tislelizumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tisotumab vedotin.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tixagevimab.The risk or severity of adverse effects can be increased when Tocilizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Toripalimab.The risk or severity of adverse effects can be increased when Tralokinumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Trastuzumab deruxtecan.The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Tremelimumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ublituximab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Ustekinumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Vedolizumab is combined with Galcanezumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Vilobelimab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Zanidatamab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Zenocutuzumab.The risk or severity of adverse effects can be increased when Galcanezumab is combined with Zolbetuximab.
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Emgality®.
Pozelimab
Adalimumab
Aducanumab
Alemtuzumab
Alirocumab
Amivantamab
Anifrolumab
Ansuvimab
Anthrax immune globulin human
Antilymphocyte immunoglobulin (horse)
Antithymocyte immunoglobulin (rabbit)
Asfotase alfa
Atezolizumab
Atoltivimab
Avelumab
Axatilimab
Bamlanivimab
Basiliximab
Belimumab
Benralizumab
Bevacizumab
Bezlotoxumab
Bimekizumab
Blinatumomab
Brentuximab vedotin
Brodalumab
Brolucizumab
Burosumab
Canakinumab
Caplacizumab
Cemiplimab
Certolizumab pegol
Cetuximab
Cilgavimab
Conjugated estrogens
Crovalimab
Daratumumab
Denosumab
Digoxin Immune Fab (Ovine)
Dinutuximab
Donanemab
Dostarlimab
Dulaglutide
Dupilumab
Durvalumab
Ebola Zaire vaccine (live, attenuated)
Eculizumab
Eflapegrastim
Eftrenonacog alfa
Elotuzumab
Emapalumab
Emicizumab
Eptinezumab
Erenumab
Esterified estrogens
Estetrol
Estradiol
Estradiol acetate
Estradiol cypionate
Estradiol valerate
Estriol
Estrone sulfate
Ethinylestradiol
Evolocumab
Fanolesomab
Fremanezumab
Gemtuzumab ozogamicin
Glofitamab
Golimumab
Guselkumab
Hepatitis B immune globulin
Human cytomegalovirus immune globulin
Human immunoglobulin G
Human Rho(D) immune globulin
Human varicella-zoster immune globulin
Ibalizumab
Ibritumomab tiuxetan
Idarucizumab
Inebilizumab
Infliximab
Inotuzumab ozogamicin
Ipilimumab
Isatuximab
Ixekizumab
Lanadelumab
Lebrikizumab
Lecanemab
Loncastuximab tesirine
Maftivimab
Margetuximab
Marstacimab
Mepolizumab
Mirvetuximab soravtansine
Mogamulizumab
Mosunetuzumab
Natalizumab
Necitumumab
Nemolizumab
Nipocalimab
Nivolumab
Obiltoxaximab
Obinutuzumab
Ocrelizumab
Odesivimab
Ofatumumab
Olaratumab
Omalizumab
Palivizumab
Panitumumab
Pembrolizumab
Penpulimab
Pertuzumab
Polatuzumab vedotin
Ramucirumab
Ranibizumab
Ravulizumab
Raxibacumab
Relatlimab
Reslizumab
Risankizumab
Rituximab
Romosozumab
Rozanolixizumab
Sacituzumab govitecan
Sarilumab
Secukinumab
Siltuximab
Sotatercept
Sotrovimab
Spesolimab
Sutimlimab
Synthetic Conjugated Estrogens, A
Synthetic Conjugated Estrogens, B
Tafasitamab
Telisotuzumab vedotin
Teplizumab
Teprotumumab
Tetanus immune globulin, human
Tezepelumab
Tildrakizumab
Tislelizumab
Tisotumab vedotin
Tixagevimab
Tocilizumab
Toripalimab
Tralokinumab
Trastuzumab
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Ublituximab
Ustekinumab
Vedolizumab
Vilobelimab
Zanidatamab
Zenocutuzumab
Zolbetuximab